Lumida
/FENC
⌘K
Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc

FENC
$10.96USD↓-3.01%-0.34 today

MARKET CAP

384.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$11 – $12

52W RANGE

$6
$13

AI Summary

Stalk
StalkMedium

FENC remains in a high-confidence Stage 2 advancing uptrend with an active momentum breakout confirming medium-term bullish structure, but price is currently extended above rising EMAs with overbought RSI and options score, making short-term execution unfavorable; deferred entries on a healthy pullback into support are advised.

  • ↑Q2 revenue rose 78% YoY to $17.1 M with net income of $1.97 M
  • ↑Non-GAAP EBITDA turned positive at $2.8 M vs a $1.2 M loss prior year
  • ↓Negative earnings yield and low book-to-price suggest overvaluation
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a specialty biopharmaceutical company that focuses on developing and commercializing PEDMARK, a drug aimed at preventing cisplatin-induced hearing loss in pediatric cancer patients. The company operates primarily in the oncology space and is strategically positioned to address unmet needs in this market segment, particularly regarding testicular cancer. With a strong emphasis on patient engagement and disease awareness, Fennec aims to enhance outcomes for young patients affected by cancer treatments.

Bull says

  • ↑Q2 revenue rose 78% YoY to $17.1 M with net income of $1.97 M
  • ↑Non-GAAP EBITDA turned positive at $2.8 M vs a $1.2 M loss prior year
  • ↑Cash & equivalents of $41.2 M bolster financial flexibility
  • ↑Dividend yield of 1.6% supports income-focused investors
  • ↑Marketing drove a 280% jump in sales calls via “Indy’s Nuts” campaign
  • ↑Analysts hold a “Buy” consensus with positive earnings revisions

Bear says

  • ↓Negative earnings yield and low book-to-price suggest overvaluation
  • ↓Profitability metrics remain weak despite revenue growth
  • ↓High leverage increases cash-flow vulnerability in downturns
  • ↓Regulatory delays and pending studies may slow market uptake
  • ↓No diversified pipeline raises disruption threat from rivals or generics
  • ↓High short interest and poor size factor reflect bearish sentiment

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 08-18-2025neutral

Transcript signals

Bull points

  • In the first quarter, Padmark delivered total net revenues of $25.4 million, including $18 million in licensing revenues from the Norgene transaction and $7.4 million in net Padmark product sales.
  • Now that this change is effective, we expect uptake to improve in the quarters to follow.
  • Regarding our partnership with Norgene to commercialize PEDMARC-C in Europe, Australia, and New Zealand, efforts are well underway in these territories with a targeted launch date at fourth quarter this year.

Bear points

  • We believe that a couple of things affected PEDMARC sales during the first quarter of this year.
  • Although Pedmark also contains boric acid, it is at a lower concentration than other STS products.
  • Unfortunately, FENIX continues to see unlawful compounding of copies of PedMart with pediatric hospital pharmacies, unnecessarily putting costs in front of children's safety.
Read full transcript analysis ›